

The US Chronic Pain Market – Focus on Opioids: Trends & Opportunities (2014-19)

<https://marketpublishers.com/r/UAD1010B308EN.html>

Date: October 2014

Pages: 68

Price: US\$ 800.00 (Single User License)

ID: UAD1010B308EN

Abstracts

Scope of the Report

The report titled “The US Chronic Pain Therapy Market: Trends & Opportunities (2014-2019)” provides an in-depth analysis of the United States chronic pain therapy market (including medication, surgeries and therapies) with detailed analysis of market sizing and growth and market share of the various drugs involved in the treatment of chronic pain. The report also assesses the key opportunities in the market and outlines the factors that are and will be driving the growth of the industry. Growth of the overall chronic pain therapy market has also been forecasted for the period 2014-19, taking into consideration the previous growth patterns, the growth drivers and the current and future trends. Further, key players of the industry like Zogenix Inc., Egalet Corporation and NektarTherapeutics are profiled.

Segment Coverage

Oxycodone

Hydrocodone

Morphine

Hydromorphone

Fentanyl

Dihydrocodeine

Methadone

Company Coverage

Zogenix Inc.

Egalet Corporation

Nektar Therapeutics

Executive summary

Chronic pain, defined as pain that lasts longer than six months and about 100 million Americans suffer from chronic pain that could be mild or agonizing, episodic or continuous, merely inconvenient or totally incapacitating.

The US chronic pain therapy market is expected to experience slow pace of growth in the near future. The major opioids used for medication in chronic pain are Oxycodone, Hydrocodone, Fentanyl, Methadone, Morphine, Hydromorphone and Dihydrocodeine. Compared to other opioids, hydrocodone products, the most commonly prescribed opioid and the most commonly prescribed pharmaceutical products in the United States, are growing at a substantial pace in the overall chronic pain therapy market. In the oxycodone business domain, the expected launch of Egalet 002 in the second quarter of 2015 by the leading player Egalet will change the dynamics of this domain as currently Oxycotin dominates the oxycodone market.

Contents

1. EXECUTIVE SUMMARY

2. INTRODUCTION: CHRONIC PAIN

3. THE US CHRONIC PAIN THERAPY MARKET

3.1 Opioid Sales in US Chronic Pain Market: Sizing & Growth

3.2 Opioid Sales in US Chronic Pain Market - Forecast: Sizing & Growth

4. THE US CHRONIC PAIN THERAPY MARKET: SEGMENT ANALYSIS

4.1 The US Oxycodone Market: Size and Growth

4.2 The US Methadone Market: Size and Growth

4.3 The US Morphine Market: Size and Growth

4.4 The US Hydromorphone Market: Size and Growth

4.5 The US Hydrocodone Market: Size and Growth

4.6 The US Dihydrocodeine Market: Size and Growth

4.7 The US Fentanyl Market: Size and Growth

5. THE US CHRONIC PAIN THERAPY: MARKET SHARE ANALYSIS

6. GROWTH DRIVERS AND CHALLENGES:THE US CHRONIC PAIN THERAPY MARKET

6.1 Growth Drivers

6.1.1 Rising Healthcare Expenditures

6.1.2 Rise in Aging Demographics

6.1.3 Economic Development

6.2 Market Challenges

7. THE US CHRONIC PAIN THERAPY MARKET TRENDS

7.1 Increasing number of Drug Approvals

7.2 Incidence of pain conditions in the US households

8. COMPETITIVE LANDSCAPE:THE US CHRONIC PAIN THERAPY MARKET

9. COMPANY PROFILES:THE US CHRONIC PAIN THERAPY MARKET

9.1 ZogenixInc

9.1.1 Business Overview

9.1.2 Financial Overview

9.1.3 Business Strategies

9.2 Egalet Corporation

9.2.1 Business Overview

9.2.2 Financial overview

9.2.3 Business Strategies

9.3 NektarTherapeutics

9.3.1 Business Overview

9.3.2 Financial overview

9.3.3 Business Strategies

List Of Tables

LIST OF TABLES AND FIGURES

Table 1: Types of Acute and Chronic pain

Table 2: WHO Guidelines for Pain Therapy

Figure 1: US Opioid Sales in Chronic Pain Therapy Market: 2009-2013 (in US\$ billions)

Figure 2: US Opioid Sales in Chronic Pain Therapy Market - Forecast: 2014F-2019F (US\$ B)

Figure 3: US Oxycodone Market: by value- 2009-2013 (in US\$ billion)

Figure 4: Oxycodone Market: Share of Leading Players (2027)

Figure 5: US Oxycodone Market: By value – Forecast: 2014F-2019F (in US\$ billion)

Figure 6: US Methadone Market: by Value- 2009-13 (in US\$ million)

Figure 7: US Methadone Market: By value – Forecast: 2014F-2019F (in US\$ million)

Figure 8: US Morphine Market: by value- 2009-13 (in US\$ million)

Figure 9: US Morphine Market: By value – Forecast: 2014F-2019F (in US\$ million)

Figure 10: US Long- Acting Morphine Market: 2014

Figure 11: US Hydromorphone Market: by Value- 2009-13 (in US\$ million)

Figure 12: US Hydromorphone Market: By value – Forecast: 2014F-2019F (in US\$ million)

Figure 13: US Hydrocodone Market: by Value- 2009-13 (in US\$ billion)

Figure 14: US Hydrocodone Market: By value – Forecast: 2014F-19F (in US\$ billion)

Figure 15: US Dihydrocodeine Market: by Value- 2009-13 (in US\$ billion)

Figure 16: US Dihydrocodeine Market: By value – Forecast: 2014F-19F (in US\$ billion)

Figure 17: US Fentanyl Market: by value- 2009-13 (in US\$ million)

Figure 18: US Fentanyl Market: By value – Forecast: - 2014F-19F (in US\$ million)

Figure 19: The US Chronic Pain Therapy Market: Share of Opioids, 2013

Figure 20: US Healthcare Expenditures per Capita, 2007-2013E (in US\$)

Figure 21: Growth of the US Aging population, 60 years and above as a percentage of total population, 2007-13E (in%)

Figure 22: US GDP, 2007-13E (in Current US\$ trillions)

Figure 23: Number of Drugs Approval by FDA, 2000-2009

Figure 24: Incidence of Pain in the US (in%)

Table 3: Leading Players of US Chronic Pain Therapy Market

Table 4: US Chronic Pain Therapy Market: Key Players and their product areas

Figure 25: Percentage share of Long Acting Morphine – Value (in %)

Table 5: Long Acting Morphine: Competition and Market Share

Table 6: US Chronic Pain Therapy Market: Sales of Leading Companies

Figure 26: Zogenix Inc. Product Revenue, FY 2011-13 (in US\$ million)

Figure 27: Zogenix Inc. R&D Expenditure, FY 2011-13 (in US\$ million)

Table 7: Products offered by Egalet

Figure 28: Egalet Revenue, FY 2011-13 (in US\$ millions)

Figure 29: Egalet R&D Expenditure, FY 2011-12 (in US\$ million)

Figure 30: Nektar Product Revenue, FY 2011-13 (in US\$ million)

Figure 31: Nektar R&D Expenditure, FY 2011-13 (in US\$ million)

I would like to order

Product name: The US Chronic Pain Market – Focus on Opioids: Trends & Opportunities (2014-19)

Product link: <https://marketpublishers.com/r/UAD1010B308EN.html>

Price: US\$ 800.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/UAD1010B308EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970